|
SG11201504410PA
(en)
|
2012-12-07 |
2015-07-30 |
Chemocentryx Inc |
Diazole lactams
|
|
BR112017003718B1
(pt)
|
2014-09-11 |
2023-04-11 |
Bristol-Myers Squibb Company |
Inibidores macrocíclicos das interações de proteína/proteína de pd- 1/pd-l1 e cd80(b7-1)/pd-l1
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
CN108135168B
(zh)
|
2015-05-21 |
2021-07-20 |
凯莫森特里克斯股份有限公司 |
Ccr2调节剂
|
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
AU2017246460B2
(en)
|
2016-04-07 |
2021-04-22 |
Chemocentryx, Inc. |
Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
SMT202100238T1
(it)
|
2016-05-19 |
2021-05-07 |
Bristol Myers Squibb Co |
Immunomodulatori per l'indagine per immagini mediante pet
|
|
EP4234691A3
(en)
|
2016-10-14 |
2023-10-18 |
Precision Biosciences, Inc. |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
|
ES2910832T3
(es)
|
2016-11-07 |
2022-05-13 |
Bristol Myers Squibb Co |
Inmunomoduladores
|
|
JP7206222B2
(ja)
*
|
2017-06-23 |
2023-01-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ－１のアンタゴニストとして作用する免疫調節剤
|
|
AR112831A1
(es)
|
2017-09-25 |
2019-12-18 |
Chemocentryx Inc |
Terapia de combinación usando un antagonista del receptor 2 de quimiocina (ccr2) y un inhibidor de pd-1 / pd-l1
|
|
WO2019070643A1
(en)
|
2017-10-03 |
2019-04-11 |
Bristol-Myers Squibb Company |
IMMUNOMODULATORS
|
|
CN111566120B
(zh)
|
2017-12-20 |
2023-09-29 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
|
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
|
|
CN112105353B
(zh)
|
2018-01-08 |
2024-04-19 |
凯莫森特里克斯股份有限公司 |
Ccr2拮抗剂治疗实体瘤的方法
|
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
|
WO2019165374A1
(en)
|
2018-02-26 |
2019-08-29 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds as hbv replication inhibitors
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
JP7388635B2
(ja)
|
2018-05-31 |
2023-11-29 |
小野薬品工業株式会社 |
免疫チェックポイント阻害薬の有効性判定バイオマーカー
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
CN108997478B
(zh)
*
|
2018-08-06 |
2021-09-21 |
中国药科大学 |
一种具有免疫检查点拮抗活性的多肽及其应用
|
|
TWI855000B
(zh)
|
2018-10-11 |
2024-09-11 |
日商小野藥品工業股份有限公司 |
Ｓｔｉｎｇ促效化合物
|
|
US11071730B2
(en)
|
2018-10-31 |
2021-07-27 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
US11203591B2
(en)
|
2018-10-31 |
2021-12-21 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
US12318403B2
(en)
|
2019-03-07 |
2025-06-03 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
US20220143061A1
(en)
|
2019-03-07 |
2022-05-12 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
KR20210146349A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
JP2022527177A
(ja)
|
2019-03-28 |
2022-05-31 |
ブリストル－マイヤーズ スクイブ カンパニー |
腫瘍を処置する方法
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
EP3972694A1
(en)
*
|
2019-05-21 |
2022-03-30 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
JP2022534981A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよび組み合わせ治療
|
|
WO2020243563A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures for suitability to immuno-oncology therapy
|
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
|
US20220283167A1
(en)
|
2019-08-05 |
2022-09-08 |
Ono Pharmaceutical Co., Ltd. |
Biomarkers for determining the efficacy of immune checkpoint inhibitors
|
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
EP4031873A1
(en)
|
2019-09-22 |
2022-07-27 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
US11497808B2
(en)
|
2019-09-30 |
2022-11-15 |
Gilead Sciences, Inc. |
HBV vaccines and methods treating HBV
|
|
KR20220093349A
(ko)
|
2019-11-08 |
2022-07-05 |
브리스톨-마이어스 스큅 컴퍼니 |
흑색종에 대한 lag-3 길항제 요법
|
|
CN114641480A
(zh)
*
|
2019-11-19 |
2022-06-17 |
百时美施贵宝公司 |
作为pd-l1抑制剂和免疫调节剂用于治疗癌症和感染性疾病的大环肽
|
|
EP4069729B1
(en)
|
2019-12-06 |
2025-01-22 |
Precision BioSciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
ES2967135T3
(es)
|
2020-01-06 |
2024-04-26 |
Bristol Myers Squibb Co |
Inmunomoduladores
|
|
CN115485288A
(zh)
*
|
2020-03-16 |
2022-12-16 |
百时美施贵宝公司 |
免疫调节剂
|
|
CN115605493A
(zh)
|
2020-03-20 |
2023-01-13 |
吉利德科学公司（Us） |
4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
|
|
EP4126902B1
(en)
|
2020-03-30 |
2023-12-06 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP4134134A4
(en)
|
2020-04-10 |
2023-12-27 |
ONO Pharmaceutical Co., Ltd. |
STING AGONISTIC COMPOUND
|
|
US20230141284A1
(en)
|
2020-04-10 |
2023-05-11 |
Ono Pharmaceutical Co., Ltd. |
Cancer therapeutic method
|
|
BR112023003427A2
(pt)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para carcinoma hepatocelular
|
|
MX2023002326A
(es)
|
2020-08-31 |
2023-03-21 |
Bristol Myers Squibb Co |
Firma de localizacion celular e inmunoterapia.
|
|
EP4216927A1
(en)
|
2020-09-22 |
2023-08-02 |
Vaccitech North America, Inc. |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
|
KR20230093282A
(ko)
|
2020-10-23 |
2023-06-27 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 lag-3 길항제 요법
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
US20240269142A1
(en)
|
2021-05-13 |
2024-08-15 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
EP4351564A1
(en)
|
2021-06-11 |
2024-04-17 |
Gilead Sciences, Inc. |
Combination mcl-1 inhibitors with anti-cancer agents
|
|
US11931424B2
(en)
|
2021-06-11 |
2024-03-19 |
Gilead Sciences, Inc. |
Combination MCL-1 inhibitors with anti-body drug conjugates
|
|
CA3222595A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2024005053A
(es)
|
2021-10-29 |
2024-05-10 |
Bristol Myers Squibb Co |
Terapia con antagonista del gen de activacion de linfocitos 3 (lag-3) para cancer hematologico.
|
|
CA3249004A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Polytherapy for Hepatocellular Carcinoma
|
|
IL315992A
(en)
|
2022-04-08 |
2024-11-01 |
Bristol Myers Squibb Co |
Identification, classification and quantification of tertiary lymphoid structures using machine learning
|
|
EP4578876A1
(en)
|
2022-08-23 |
2025-07-02 |
ONO Pharmaceutical Co., Ltd. |
Bispecific antibody
|
|
AU2023409221A1
(en)
|
2022-12-21 |
2025-06-12 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|